EVENTS | VIEW CALENDAR
QIAGEN bolsters its database offerings with Ingenuity acquisition
HILDEN, GermanyŚQIAGEN N.V. has announced this week the acquisition of Ingenuity Systems, Inc., a Redwood City, Calif.-based software solutions provider. No financial details were disclosed.
Ingenuity is a privately held company that boasts a market-leading knowledge system of biomedical information and analysis solutions to aid users in interpreting and analyzing complex biological systems.
"The interpretation of biological information is becoming a cornerstone of QIAGEN's ecosystem of Sample & Assay Technologies for molecular testing - both in life sciences research and in diagnostics. We are establishing a leading role in this field and intend to further expand the value proposition and scope of our offering," Peer M. Schatz, CEO of QIAGEN N.V., said in a press release.
"Ingenuity has created unparalleled leadership with its Knowledge Base and interpretation solutions to unlock the value of complex genomic and other biological information. Combining the highest-quality knowledge content with powerful search capabilities and easy-to-use interfaces, the Ingenuity suite provides customers with scientifically and clinically relevant insights into diseases," he continued. "We are looking forward to expanding the seamless integration of leading biomedical information solutions into our full range of molecular testing solutions, thereby providing our customers a unique experience from sample to interpreted result and recommendations for next steps. Integration of Ingenuity's solutions into a powerful, full-range ecosystem of QIAGEN's molecular testing solutions, such as PCR and next-generation sequencing, promises to offer significant value to QIAGEN customers and shareholders."
Ingenuity's product portfolio is based on its Ingenuity Knowledge Base, which sought to manually curate, model and computationally structure biomedical literature, including genomic variations found in human diseases. It consists of algorithms that pair all human gene variations with biological interpretations established with known outcomes. The pairings are reviewed by experts in a standardized format, and the resulting data is translated into interwoven collections. This collection and its software applications enable more accurate, simpler interpretation of the reams of data that result from genomics and next-generation sequencing in the study and analysis of diseases and disease models.
Among Ingenuity's product offerings are Ingenuity Pathways Analysis, for the modeling and analysis of biological systems in life-sciences research; Ingenuity Variant Analysis, a web-based next-generation sequencing data analysis application that aids in the rapid identification of relevant causal variants in human diseases; and Ingenuity iReport, an interactive web-based report that is optimized for gene expression experiments from RNA-Seq, microarray and real-time PCR platforms.
Ingenuity's data and analysis offerings will expand on QIAGEN's own curated database and its GeneGlobe content portal, which provides hundreds of assay panels for PCR and next-generation sequencing in addition to more than 60,000 fully annotated molecular assays for the most popular diseases and pathways.
"Today we can sequence an entire human genome in just a couple of days for less than a few thousand dollars, but the data analysis can take from months to years. The Ingenuity suite of products enables this rapid and accurate interpretation in a matter of minutes, and this is fundamentally impacting scientific research and the ability to diagnose and manage patient care," Jake Leschly, president and CEO of Ingenuity Systems, commented in a statement. "The Ingenuity mission from day one has been to accelerate scientific discovery and enhance clinical decision-making through a rich understanding of biological systems. As part of QIAGEN, we will offer our biological knowledge content and software in the context of a best-in-class ecosystem of molecular testing solutions and to a greatly expanded range of customers around the world."
SOURCE: QIAGEN press release